, Leon Kircik, MD, clinical professor of 

 at the Icahn School of Medicine at Mount Sinai and medical director of DermResearch, Physicians Skin Care, and Skin Sciences in Louisville, Kentucky, joined Lisa Swanson, MD, for a talk on molluscum contagiosum and berdazimer topical gel, 10.3%.

Kircik said molluscum contagiosum, a poxvirus infection mostly affecting young children, had no 

-approved treatment until recently, leaving clinicians to rely on irritating topical agents or physical modalities such as curettage, cryotherapy, trichloroacetic acid, and liquid nitrogen.

Why Molluscum No Longer Means Watch and Wait, With Leon Kircik, MD

Those visits often come with an anxious parent in the room, he said, since many families first hear from a pediatrician the virus will simply resolve on its own within a year or more.

"It looks very simple, but it's a very challenging diagnosis to deal with and treat," Kircik said.

Kircik said those physical options are especially hard to carry out in 2- and 3-year-old patients, who need to be held still, and berdazimer gel, 10.3%, gives families an FDA-approved option they can apply at home instead. He was careful to frame it as a treatment rather than a cure, since molluscum is viral and no product yet clears the infection directly. Kircik said pediatric dermatology broadly draws less drug-development attention, noting warts still have no FDA-approved treatment of their own despite affecting more than 20 million people in the US each year.

Kircik said he follows ongoing clinical research closely and expects additional molluscum therapies to reach the armamentarium in coming years, though he did not name specific candidates. He also praised LEADderm's format for opening with sessions like his own before the scientific program, calling the mix a grounding complement to the clinical data covered later on.

Asked what excites him most in dermatology broadly, Kircik pointed to alopecia areata, an area he said went overlooked for years. He noted 3 JAK inhibitors, baricitinib, ritlecitinib, and deuruxolitinib, are now FDA-approved for the condition, and said he is looking forward to a biologic option offering long-term efficacy and safety for patients who need ongoing treatment.

Editor’s note: Kircik has disclosed receiving research funding, honoraria, and speaking fees from Novan, Inc., and its successor, Pelthos Therapeutics, maker of berdazimer.

FDA approves Zelsuvmi (berdazimer) topical gel, 10.3%, for molluscum contagiosum. Drugs.com. Updated January 5, 2024.

Pelthos Therapeutics launches Zelsuvmi (berdazimer) topical gel, 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. Pelthos Therapeutics. Published July 10, 2025. Accessed September 8, 2026. 

https://pelthos.com/pelthos-therapeutics-launches-zelsuvmi-berdazimer-topical-gel-10-3-the-first-and-only-fda-approved-at-home-treatment-for-molluscum-contagiosum/

Aboul-Fettouh N. Choosing among approved JAK inhibitors: baricitinib, ritlecitinib, and deuruxolitinib. HCPLive. June 23, 2026. Accessed September 8, 2026. 

https://www.hcplive.com/view/choosing-among-approved-jak-inhibitors-baricitinib-ritlecitinib-and-deuruxolitinib

Videos

Leon Kircik, MD, on why an FDA-approved, at-home molluscum option changes practice, and what is exciting for him in dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Why Molluscum No Longer Means 'Watch and Wait,' With Leon Kircik, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

European Society of Cardiology (ESC) Congress 2026

, in Munich, Germany, was a hotbed for major trial readouts and key cardiology news. With hundreds of late-breaking and Hot Line sessions over 4 days of the conference, a plethora of headlines were presented almost at once. From 

 and amyloidosis, ESC 2026 saw updates in just about every major subspecialty within the larger cardiology field.

With so much news coming out of this conference, it was easy to miss even some of the biggest stories and presentations. After our on-site coverage of the full congress, the 

 editorial team has collected 5 of the most impactful headlines from ESC 2026 that you may have missed below:


Aficamten Safe, Efficacious in nHCM, Improves Symptoms and Exercise Capacity

Full results from the ACACIA-HCM trial were presented at ESC 2026 by Ahmad Masri, MD, MS, the cardiomyopathy section head at Oregon Health & Science University and director of the OHSU hypertrophic cardiomyopathy center. This trial compared aficamten to placebo in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) – patients receiving aficamten saw substantial improvements in symptom burden and exercise capacity.


SHASTA-3/4: What an 80% Triglyceride Cut Means, With Christie Ballantyne, MD

Plozasiran and Severe Hypertriglyceridemia in SHASTA 3/4, With Christie Ballantyne, MD

The SHASTA-3 and SHASTA-4 trials, which investigated RNAi therapeutic plozasiran for patients with severe hypertriglyceridemia, both achieved their primary endpoints of triglyceride reductions. In SHASTA-3, treatment led to a 79% reduction by month 12, while SHASTA-4 saw 81% reductions by the same period. In comparison, placebo achieved around 27% in both trials. In an interview with 

 Christie Ballantyne, MD, professor of medicine, genetics, and physiology at Baylor College of Medicine, explains what these results mean in practice.


The Future of Gene Silencers for ATTR-CM After CARDIO-TTRansform, With Ronald Witteles, MD

Do TTR Silencers Still Work? With Ronald Witteles, MD

The CARDIO-TTRansform study, which investigated the RNA-targeted gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), failed to achieve its primary composite endpoint of cardiovascular mortality and recurrent events, despite suppressing circulating serum TTR. However, the HELIOS-B trial, which demonstrated the efficacy and safety of the silencer vutrisiran, achieved both its primary and all 4 secondary endpoints years prior. To address this contradiction, Ronald Witteles, MD, of Stanford Medicine, spoke with 

 and explained that, despite recent stumbles, silencer therapies are still extremely viable.


TRANQUILITY: Pacibekitug Reduces hs-CRP, Inflammatory Biomarkers in CKD

These data, presented by Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital, highlighted the efficacy of pacibekitug in reducing inflammatory biomarkers in patients with 

 at high inflammatory risk. After 30 days of treatment, patients receiving pacibekitug saw significant dose-dependent decreases in hs-CRP, which were sustained through 180 days of follow-up. However, TRANQUILITY was not powered for cardiovascular events – to this end, in an interview with 

, Bhatt discusses the need for further trials to investigate pacibekitug’s potential cardioprotective effects.


STAREE: Statins Reduce Cardiovascular Events But Not Disability in Older Adults

Atorvastatin successfully reduced major cardiovascular events compared to placebo in patients ≥70 years of age without known cardiovascular disease, 

, or dementia in the STAREE trial – however, it failed to improve disability-free survival. STAREE was the first large randomized controlled trial to test statin therapy specifically in older adults, and as such the presentation at ESC 2026 aimed to provide evidence to guide the rapidly-aging US population through cardiovascular risk.

Articles

ESC Congress 2026 featured several practice-relevant trial readouts across cardiomyopathy, dyslipidemia, amyloidosis, inflammation, and preventive cardiology. In non-obstructive hypertrophic cardiomyopathy, aficamten improved symptom burden and exercise capacity versus placebo. RNAi therapy plozasiran produced ~80% triglyceride reductions in severe hypertriglyceridemia. In ATTR-CM, eplontersen suppressed TTR yet missed a primary composite outcome, contrasting with prior positive vutrisiran data. Pacibekitug lowered hs-CRP in high-risk CKD, while STAREE showed atorvastatin reduced events without improving disability-free survival in older adults.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ESC 2026 Recap: 5 Practice-Changing Trials to Know

Acute kidney injury (AKI) remains managed largely through supportive care, without approved therapies aimed directly at the underlying injury and repair processes. The condition contributes to up to 20% of hospital admissions and can progress toward 

when recovery is incomplete.¹ Few experimental systems allow investigators to control an ischaemic insult in human kidney tissue and then track how individual cell populations respond and recover, particularly across the acute and post-injury phases.

Alexander Combes, PhD, head of the Development and Disease Laboratory at Monash Biomedicine Discovery Institute, led development of a human kidney organoid model reproducing ischaemic AKI, published August 19, 2026, in 

.² Incorporating human macrophages alongside nephron cell types, the model used single-cell and spatial profiling to show injury disrupted normal cell identity, though podocyte and distal tubule markers largely recovered after reoxygenation. Proximal tubule cells showed a more heterogeneous response, with some populations retaining injury-associated and inflammatory programs instead of returning to baseline, and macrophages exposed to the model shifted toward activated inflammatory states.

For nephrologists, the model offers a human platform to investigate why proximal tubule cells are disproportionately prone to incomplete repair, a pattern implicated in progression from AKI to CKD. "By recreating these responses in miniature human kidneys, we can investigate what drives healthy recovery versus persistent damage, and identify ways to intervene," Combes said in a statement.¹ 

Combes spoke with HCPLive about the organoid model, the biology driving incomplete proximal tubule repair, and what it means for future AKI therapies.

Q&A: Modeling AKI injury and recovery in kidney organoids

 What gap in AKI research were you trying to address with this model?

 Much of what we know about AKI comes from clinical studies and animal models, both of which are essential, but there are relatively few experimental human systems where we can control the injury and then follow how different kidney cell types respond and recover. We wanted to determine whether human kidney organoids could fill some of that gap by reproducing clinically relevant features of ischaemic AKI in a system where we can study the underlying mechanisms and, ultimately, test potential therapies.

 What would you say are the most important findings from this study?

 Previous studies had shown that kidney organoids can reproduce generic features of AKI. We extended this into a defined ischaemic injury model and found that, importantly, the organoids did not fully recover after injury. Instead, they retained persistent injury-associated epithelial states linked to the transition from AKI to chronic kidney disease. Capturing both the acute injury phase and these persistent post-injury states is important because it creates opportunities to screen for drugs that either prevent injury in the first place or improve recovery afterwards. We also incorporated human macrophages and found that injury drove them towards activated inflammatory states, providing a way to study interactions between injured kidney cells and the immune system.

 Why did proximal tubule cells recover less completely than podocytes or the distal tubule after injury?

 We used single-cell and spatial profiling to look at individual kidney cell populations during injury and recovery. Hypoxia initially disrupted normal cell identity and function across nephron cell types. After return to normal oxygen conditions, markers of podocyte and distal tubule identity largely recovered. In contrast, proximal tubule cells showed a more heterogeneous response: some recovered towards their normal state, while others retained injury-associated and inflammatory programs. That is interesting because the proximal tubule is particularly vulnerable in human AKI and is thought to play an important role in determining whether the kidney successfully repairs or progresses towards persistent dysfunction. Organoids do not recreate that entire clinical process, but it gives us a human experimental system to investigate why some tubular cells recover while others remain in an altered state.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Combes reported no relevant disclosures.

Monash University. Miniature kidneys could accelerate new treatments for acute kidney injury. News release. August 20, 2026. Accessed September 8, 2026. 

https://www.eurekalert.org/news-releases/1140789

Nunez-Nescolarde AB, et al. Modelling ischaemic AKI in human kidney organoids reveals injury-associated epithelial states and macrophage-epithelial crosstalk. Genome Med. 2026;doi:10.1186/s13073-026-01712-z

Acute kidney injury lacks disease-modifying therapies and often progresses to CKD when repair is incomplete, underscoring the need for controllable human experimental systems. A human kidney organoid platform was engineered to model ischaemic AKI with reoxygenation recovery, integrating macrophages and leveraging single-cell and spatial profiling. Hypoxia disrupted nephron identity broadly, with podocyte and distal tubule programs largely restoring after reoxygenation. Proximal tubules recovered heterogeneously; subsets persisted in injury-associated inflammatory states. Macrophages adopted activated inflammatory phenotypes, enabling study of immune–epithelial crosstalk and therapeutic screening.

 Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD

Sharmila Dorbala, MD, MPH, is the director of nuclear cardiology at Brigham and Women’s Hospital and the director of amyloidosis research at Mass General Brigham Heart & Vascular Institute.

I-124 evuzamitide positron emission tomography (PET)/computed tomography (CT) is both highly sensitive and specific in diagnosing 

 while maintaining an acceptable safety profile.

REVEAL: I-124 Evuzamitide PET/CT Specific, Sensitive for Cardiac Amyloidosis Diagnosis

 in Munich, Germany, by Sharmila Dorbala, MD, MPH, director of nuclear cardiology at Brigham and Women’s Hospital and director of amyloidosis research at Mass General Brigham Heart & Vascular Institute, these data represent the culmination of the phase 3 REVEAL trial.

“I think this is a huge leap from the previous scenario, where we had multiple complex tests interpreted by different folks,” Dorbala told 

 in an exclusive interview. “With this particular approach, it doesn’t matter where the patient goes, but if cardiac amyloid is in the differential and you perform a PET scan, you may be able to detect amyloid deposits in multiple organ systems. Therefore, this approach can potentially reduce the time to diagnosis significantly.”

REVEAL was an open-label multicenter evaluation of I-124 evuzamitide as a PET imaging agent. Dorbala and colleagues enrolled patients ≥18 years of age who were suspected of having cardiac amyloidosis and were or would undergo a diagnostic evaluation of any kind. Patients were excluded if they had an established diagnosis of cardiac amyloidosis or systemic amyloidosis with known organ involvement, among other criteria.

The trial was divided into a primary and safety analysis and an image-evaluable analysis. The primary endpoints of the study were the specificity and sensitivity of PET/CT imaging with I-124 evuzamitide ≤60 days following administration based on visual scan interpretations. Secondary endpoints included specificity and sensitivity for the diagnosis of ATTR amyloidosis and AL amyloidosis, as well as the incidence of treatment-emergent adverse events ≤30 days after administration.

A total of 195 patients were enrolled at 18 sites across the US, of whom 170 were ultimately included in the safety and intent-to-image cohorts following administration and PET/CT imaging. Of these patients, 76 (44.7%) had cardiac amyloidosis – 54 with ATTR, 21 with light chain, and 1 with indeterminate type – and 93 *54.7%) did not, based on the truth standard consensus.

Dorbala and colleagues found that overall majority-decision sensitivity was 94% (95% CI, 85-98%), while specificity was 86% (95% CI, 77-92%). Positive predictive value was 85% (95% CI, 75-92%), and negative predictive value was 94% (95% CI, 87-98%). All 4 values were consistent across the individual readers. Additionally, the secondary endpoints in ATTR and AL amyloidosis also met the predefined success criteria – among the 54 patients with confirmed ATTR amyloidosis, 52 had positive imaging by majority decision, and of the 21 with AL amyloidosis, 20 had positive imaging.

Among the 170 patients receiving I-124 evuzamitide, 55 (32.4%) exhibited ≥1 treatment-emergent adverse event by day 30. Of these patients, 11 (6.5%) had a serious event, and only 1 – fatigue – was considered relevant to the treatment. Additionally, no deaths occurred during the study period, and none of the serious adverse events were related to I-124 evuzamitide.

Ultimately, Dorbala and colleagues concluded that this imaging strategy is extremely effective in identifying these patients, with an excellent safety profile and substantial specificity and sensitivity. Dorbala also expressed excitement for the future of amyloidosis treatment following this trial, as she believes it demonstrates a significant step forward in diagnosis that will allow for more focus on treatment.

“In order to do all of this, we will need to perform randomized clinical trials of treatment in these patients to see what the optimal time is to initiate therapy in some of these patients who don’t have symptoms or who don’t have changes on echo or MRI,” Dorbala said. “It’s a very exciting time for the field to be able to, as a first step, detect these early deposits, but the future is going to be more exciting, since we’ll need more trials to study whether we can prevent cardiac amyloid heart failure by early therapy.”

Editors’ Note: Dorbala reports disclosures with Attralus, AstraZeneca, BridgeBio, GE Healthcare, Medtrace, Pfizer, and others.

Dorbala S. A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis. Presented at the European Society of Cardiology (ESC) Congress 2026, Munich, Germany. August 28-31, 2026.

Dorbala S. REVEAL – Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL). ClinicalTrials.gov Identifier: NCT06788535. Updated April 30, 2026. Accessed September 8, 2026. 

https://clinicaltrials.gov/study/NCT06788535

Dorbala S, Maurer MS, Cuddy SA, et al. I-124 evuzamitide positron emission tomography/computed tomography for diagnosing cardiac amyloidosis. 

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Spyre Therapeutics has reported positive 12-week induction results from Part A of the Phase 2 SKYLINE trial evaluating SPY003, an investigational anti-IL-23 antibody, in patients with moderately-to-severely active 

. According to the press release, this readout completes proof-of-concept for all 3 components of Spyre's 

 combination pipeline, following earlier positive Part A results for SPY001 (anti-α4β7) and SPY002 (anti-TL1A).

“SPY003 demonstrated a highly statistically significant 10-point reduction in RHI and meaningful clinical remission and endoscopic outcomes in line with the anti-IL-23 class,” Deanna Nguyen, MD, senior vice president of clinical development and SKYLINE study lead, said in a statement. “Combined with a well-tolerated safety profile and extended pharmacokinetics in alignment with the rest of our portfolio, these results position SPY003 as a potentially best-in-class combination component for patients with moderately-to-severely active UC.”

How SPY003 Targets IL-23 in Ulcerative Colitis

SPY003 is an extended half-life investigational antibody targeting IL-23, a cytokine implicated in chronic inflammation in IBD. By blocking IL-23 signaling, the antibody is designed to reduce the downstream immune activity that drives tissue damage in UC, a mechanism shared with other approved and investigational agents in the anti-IL-23 class.

SKYLINE-UC Trial Design and Patient Population

SKYLINE-UC is a 2-part induction and maintenance platform trial assessing SPY001, SPY002, SPY003, and pairwise combinations of the 3 agents in patients with moderately-to-severely active UC. Part A is an open-label evaluation of a single dose level of each monotherapy, and Part B, which is actively enrolling, is a randomized, placebo-controlled assessment of 2 dose levels of each monotherapy along with 3 combination arms.

Among the 44 participants who received SPY003 through the July 27, 2026, data cutoff, 41% had prior exposure to advanced therapy, and mean disease duration was 7.1 years. The population had a mean baseline Robarts Histopathology Index (RHI) score of 17.2 (± 8.3), a mean baseline modified Mayo Score of 6.9 (± 1.2), and 59% had a baseline endoscopy subscore of 3.

SPY003 Efficacy Results in Ulcerative Colitis

SPY003 met its primary endpoint, achieving a 10.0-point reduction in RHI score from baseline at week 12 (

 < .0001). Secondary endpoints included a clinical remission rate of 20% by modified Mayo Score and an endoscopic improvement rate of 30%; the modified Mayo Score itself decreased by 3.5 points.

The 10.0-point RHI reduction with SPY003 was consistent with the 9.2-point and 10.7-point reductions previously reported for SPY001 and SPY002, respectively. According to Spyre, all 3 results are among the largest RHI improvements observed in UC trials to date.

SPY003 was well tolerated, with a safety profile consistent with the anti-IL-23 class. Of the 44 participants, 19 (43%) had a treatment-emergent adverse event (TEAE) during induction, and 3 serious adverse events (SAEs), none deemed drug-related, were reported: hospitalization for a UC flare, hemorrhoid thrombosis, and acute cholecystitis. The most common adverse events, each occurring in 2 patients, were arthralgia, nasopharyngitis, and urinary tract infection. No patients discontinued treatment due to an adverse event, and no deaths occurred.

SPY001 and SPY002 were previously reported as well tolerated in Part A, each with safety profiles consistent with their respective drug classes and no drug-related SAEs.

Next Steps: SKYLINE Part B and Spyre's IBD Pipeline

With clinical proof-of-concept now established for all 3 mechanisms, SKYLINE Part B will evaluate 2 dose levels of each monotherapy alongside 3 high-dose combination arms (SPY120, SPY130, and SPY230). Spyre expects topline induction data from Part B in 2027.

The company also has readouts expected for SPY072 in psoriatic arthritis and axial spondyloarthritis (SKYWAY trial) in the fourth quarter of 2026, and for SPY072 plus an IL-17A/F agent in hidradenitis suppurativa (SKYLIGHT trial) in late 2027 or early 2028.

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations. News release. Spyre Therapeutics, Inc. September 8, 2026. 

https://ir.spyre.com/news-releases/news-release-details/spyre-announces-potential-best-class-spy003-anti-il-23-part

A Study of Long-Acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (SKYLINE-UC). ClinicalTrials.gov identifier: NCT07012395. Updated 2026. 

https://clinicaltrials.gov/study/NCT07012395

Spyre’s extended half-life anti–IL-23 antibody SPY003 produced a highly statistically significant histologic response in moderately-to-severely active ulcerative colitis, with a 10.0-point Robarts Histopathology Index reduction at week 12 and accompanying clinical remission and endoscopic improvement. The open-label Part A SKYLINE-UC cohort included substantial prior advanced-therapy exposure and notable baseline endoscopic severity. Safety aligned with the anti–IL-23 class, with no drug-related serious adverse events or discontinuations. Randomized, placebo-controlled Part B will test dose-ranging monotherapy and high-dose combinations.

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

David T. Rubin, MD is a professor of medicine at the University of Chicago, director of the Inflammatory Bowel Disease Center, and chair of the International Organization for the Study of IBD (IOIBD).

David T. Rubin, MD, on the screening tools, direct questions, and therapy choices behind IBD's three tiers of remission.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Deucrictibant XR Meets Primary Endpoint in HAE Prophylaxis

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

FDA News

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD

The FDA granted lonvo-z priority review for HAE, setting a PDUFA date of March 10, 2027 based on positive Phase 3 HAELO data.

Lonvo-z BLA Accepted by FDA With Priority Review for HAE

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

Arrhythmia

TactiFlex Duo Ablation Catheter Receives FDA Approval for AFib

Ross M. Levy, MD, serves as a dermatologist at Endeavor Health in Illinois, specializing in cosmetic and surgical dermatology with expertise in Mohs surgery for skin cancer.

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study

Evidence places biologics at GINA Step 5, and that is where reimbursement holds them. Dr. Hanania and Dr. Wechsler examine the case for moving earlier, and what it would require.

Video Series

Positioning Biologics in Asthma: GINA Step 5 and Earlier Treatment

This episode, "Redefining Treatment Success in IgAN: Remission and Life Beyond Steroids," features the panel reframing the goals of care.

Redefining Treatment Success in IgAN: Remission and Life Beyond Steroids

Seven approved agents across four targets, spanning two decades of approvals. Dr. Wechsler maps the class, then names the 40% of exacerbations it still does not prevent.

Latest News

Why Molluscum No Longer Means 'Watch and Wait,' With Leon Kircik, MD

ESC 2026 Recap: 5 Practice-Changing Trials to Know

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD

REVEAL: I-124 Evuzamitide PET/CT Specific, Sensitive for Cardiac Amyloidosis Diagnosis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis